Kingworld Medicines Group Limited

SEHK:1110 Stock Report

Market Cap: HK$317.5m

Kingworld Medicines Group Past Earnings Performance

Past criteria checks 4/6

Kingworld Medicines Group's earnings have been declining at an average annual rate of -4.3%, while the Healthcare industry saw earnings growing at 4.8% annually. Revenues have been growing at an average rate of 1% per year. Kingworld Medicines Group's return on equity is 8.8%, and it has net margins of 3.5%.

Key information

-4.3%

Earnings growth rate

-3.2%

EPS growth rate

Healthcare Industry Growth11.3%
Revenue growth rate1.0%
Return on equity8.8%
Net Margin3.5%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Mar 22
A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

Nov 30
The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Aug 17
Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

May 30
Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

May 11
The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Apr 03
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

Feb 07
Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Oct 07
A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Jul 05
Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

Apr 27
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Aug 17
We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Apr 24
Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Mar 29
Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Mar 08
Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

Feb 15
Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

Jan 25
Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?

Dec 18
Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?

We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt

Dec 05
We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt

What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation

Nov 22
What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation

Revenue & Expenses Breakdown
Beta

How Kingworld Medicines Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SEHK:1110 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 231,079382230
30 Sep 231,085372180
30 Jun 231,091362130
31 Mar 231,024292100
31 Dec 22958232060
30 Sep 22905292030
30 Jun 22852352000
31 Mar 22850331980
31 Dec 21847301960
30 Sep 21858262220
30 Jun 21868212480
31 Mar 21807172470
31 Dec 20745122460
30 Sep 20749162270
30 Jun 20752202080
31 Mar 20865322140
31 Dec 19978432200
30 Sep 191,010452210
30 Jun 191,041462220
31 Mar 191,060442370
31 Dec 181,079412520
30 Sep 181,079492640
30 Jun 181,079562770
31 Mar 181,055542640
31 Dec 171,031512510
30 Sep 171,088502400
30 Jun 171,145492290
31 Mar 171,099482270
31 Dec 161,054472250
30 Sep 16909412090
30 Jun 16764351930
31 Mar 16739341820
31 Dec 15714321710
30 Sep 15711341630
30 Jun 15708361550
31 Mar 15684371440
31 Dec 14660381340
30 Sep 14640431260
30 Jun 14619481190
31 Mar 14587481150
31 Dec 13555471120
30 Sep 13571471090
30 Jun 13587481060

Quality Earnings: 1110 has high quality earnings.

Growing Profit Margin: 1110's current net profit margins (3.5%) are higher than last year (2.4%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1110's earnings have declined by 4.3% per year over the past 5 years.

Accelerating Growth: 1110's earnings growth over the past year (67.5%) exceeds its 5-year average (-4.3% per year).

Earnings vs Industry: 1110 earnings growth over the past year (67.5%) exceeded the Healthcare industry 13.4%.


Return on Equity

High ROE: 1110's Return on Equity (8.8%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.